ケース・スタディ

The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.

Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express the protein of interest at desired levels. This case study illustrates the successful generation of a tag-free vaccine protein.

Biointron has developed our own CHOK1-Fut8KO expression platform for afucosylated antibodies.

Biointron established a single-B cell antibody discovery platform based on microfluidic technology. Combined with our proprietary fast antibody expression platform, it has been proven to be fast and efficient in many projects.

Biointron has developed a successful method for discovering alpaca VHH for over 200 projects, using flexible immunization strategies and a robust phage display screening platform.